Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • United Therapeutics' Cash & Equivalents fell 1375.89% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 1375.89%. This contributed to the annual value of $1.7 billion for FY2024, which is 4053.16% up from last year.
  • Per United Therapeutics' latest filing, its Cash & Equivalents stood at $1.3 billion for Q3 2025, which was down 1375.89% from $1.6 billion recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Cash & Equivalents registered a high of $1.9 billion during Q1 2025, and its lowest value of $795.2 million during Q2 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $1.1 billion (2023), whereas its average is $1.2 billion.
  • Per our database at Business Quant, United Therapeutics' Cash & Equivalents plummeted by 1560.18% in 2022 and then surged by 5180.98% in 2025.
  • Over the past 5 years, United Therapeutics' Cash & Equivalents (Quarter) stood at $894.8 million in 2021, then increased by 7.42% to $961.2 million in 2022, then increased by 25.65% to $1.2 billion in 2023, then soared by 40.53% to $1.7 billion in 2024, then decreased by 21.04% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q3 2025, $1.6 billion for Q2 2025, and $1.9 billion during Q1 2025.